

1. Sales January to June 2009 and 2008

| January – June           | 2009   | 2008   | % change |                     |
|--------------------------|--------|--------|----------|---------------------|
|                          | CHF m  | CHF m  | In CHF   | In local currencies |
| Pharmaceuticals Division | 19,104 | 17,257 | +11      | +11                 |
| Europe/Rest of World     | 9,404  | 9,232  | +2       | +11                 |
| US                       | 7,516  | 6,573  | +14      | +6                  |
| Japan                    | 2,184  | 1,452  | +50      | +27                 |
| Diagnostics Division     | 4,902  | 4,747  | +3       | +7                  |
| Roche Group              | 24,006 | 22,004 | +9       | +10                 |

2. Quarterly local sales growth by Division in 2008 and 2009

|                          | Q3 2008<br>vs. Q3 2007 | Q4 2008<br>vs. Q4 2007 | Q1 2009<br>vs. Q1 2008 | Q2 2009<br>vs. Q2 2008 |
|--------------------------|------------------------|------------------------|------------------------|------------------------|
| Pharmaceuticals Division | +8                     | +5                     | +8                     | +14                    |
| Europe/Rest of World     | +7                     | +10                    | +8                     | +14                    |
| US                       | +12                    | 0                      | +1                     | +12                    |
| Japan                    | -1                     | +5                     | +40                    | +16                    |
| Diagnostics Division     | +11                    | +9                     | +8                     | +7                     |
| Roche Group              | +9                     | +6                     | +8                     | +12                    |

3. Quarterly sales by Division in 2008 and 2009

| CHF millions             | Q2 2008 | Q3 2008 | Q4 2008 | Q1 2009 | Q2 2009 |
|--------------------------|---------|---------|---------|---------|---------|
| Pharmaceuticals Division | 8,689   | 8,936   | 9,768   | 9,216   | 9,888   |
| Europe/Rest of World     | 4,661   | 4,637   | 4,727   | 4,491   | 4,913   |
| US                       | 3,247   | 3,517   | 3,939   | 3,586   | 3,930   |
| Japan                    | 781     | 782     | 1,102   | 1,139   | 1,045   |
| Diagnostics Division     | 2,460   | 2,365   | 2,544   | 2,361   | 2,541   |
| Roche Group              | 11,149  | 11,301  | 12,312  | 11,577  | 12,429  |

4. Top 20 Pharmaceuticals Division product sales and local growth<sup>1</sup> in YTD June 2009: US, Japan and Europe/Rest of World

|                    | Total    |      | US       |      | Japan    |       | Europe/RoW |      |
|--------------------|----------|------|----------|------|----------|-------|------------|------|
|                    | CHF<br>m | %    | CHF<br>m | %    | CHF<br>m | %     | CHF<br>m   | %    |
| MabThera/Rituxan   | 3,098    | 8%   | 1,578    | 6%   | 115      | 3%    | 1,405      | 10%  |
| Avastin            | 3,090    | 29%  | 1,693    | 20%  | 182      | 116%  | 1,215      | 36%  |
| Herceptin          | 2,645    | 10%  | 810      | 6%   | 174      | 51%   | 1,661      | 10%  |
| Tamiflu            | 1,010    | 203% | 317      | 11%  | 300      | 1510% | 393        | 869% |
| CellCept           | 927      | -8%  | 396      | -20% | 24       | 11%   | 507        | 2%   |
| Pegasys            | 842      | 10%  | 208      | 10%  | 65       | 33%   | 569        | 8%   |
| NeoRecormon/Epogin | 789      | -10% | -        | -    | 246      | -4%   | 543        | -13% |
| Tarceva            | 643      | 10%  | 253      | -3%  | 32       | 37%   | 358        | 18%  |
| Xeloda             | 626      | 11%  | 224      | 12%  | 33       | 38%   | 369        | 9%   |
| Lucentis           | 573      | 21%  | 573      | 21%  | -        | -     | -          | -    |
| Bonviva/Boniva     | 525      | 3%   | 291      | -13% | -        | -     | 234        | 30%  |
| Xolair             | 313      | 12%  | 313      | 12%  | -        | -     | -          | -    |
| Valcyte/Cymevene   | 274      | 7%   | 132      | 5%   | -        | -     | 142        | 8%   |
| Pulmozyme          | 248      | 6%   | 148      | 9%   | -        | -     | 100        | 2%   |
| Activase/TNKase    | 226      | 31%  | 204      | 34%  | -        | -     | 22         | 10%  |
| Nutropin           | 211      | 1%   | 206      | 2%   | -        | -     | 5          | -6%  |
| Xenical            | 209      | -12% | 18       | -35% | -        | -     | 191        | -10% |
| Neutrogen          | 188      | -17% | -        | -    | 188      | -17%  | -          | -    |
| Rocephin           | 164      | -7%  | 1        | -78% | 32       | -3%   | 131        | -6%  |
| Madopar            | 140      | -3%  | -        | -    | 11       | 5%    | 129        | -3%  |

<sup>1</sup> versus YTD June 2008

5. Top 20 Pharmaceuticals Division quarterly local product sales growth in 2008 and 2009

|                    | Q3 2008<br>vs. Q3 2007 | Q4 2008<br>vs. Q4 2007 | Q1 2009<br>vs. Q1 2008 | Q2 2009<br>vs. Q2 2008 |
|--------------------|------------------------|------------------------|------------------------|------------------------|
| MabThera/Rituxan   | 15%                    | 16%                    | 6%                     | 10%                    |
| Avastin            | 37%                    | 36%                    | 30%                    | 29%                    |
| Herceptin          | 14%                    | 12%                    | 11%                    | 10%                    |
| Tamiflu            | -56%                   | -65%                   | 38%                    | 1048%                  |
| CellCept           | 14%                    | 11%                    | 7%                     | -21%                   |
| Pegasys            | 12%                    | 5%                     | 9%                     | 10%                    |
| NeoRecormon/Epogin | -15%                   | -8%                    | -13%                   | -8%                    |
| Tarceva            | 18%                    | 19%                    | 13%                    | 7%                     |
| Xeloda             | 14%                    | 12%                    | 8%                     | 14%                    |
| Lucentis           | 15%                    | 19%                    | 21%                    | 21%                    |
| Bonviva/Boniva     | 26%                    | 23%                    | 3%                     | 2%                     |
| Xolair             | 12%                    | 13%                    | 13%                    | 11%                    |
| Valcyte/Cymevene   | 13%                    | 9%                     | 7%                     | 6%                     |
| Pulmozyme          | 6%                     | 14%                    | 3%                     | 8%                     |
| Activase/TNKase    | -2%                    | 13%                    | 45%                    | 17%                    |
| Nutropin           | 1%                     | -1%                    | 1%                     | 2%                     |
| Xenical            | -9%                    | -11%                   | -14%                   | -10%                   |
| Neutrogen          | 0%                     | -13%                   | -22%                   | -13%                   |
| Rocephin           | -16%                   | -6%                    | -15%                   | 2%                     |
| Madopar            | 4%                     | 3%                     | 0%                     | -5%                    |

6. Pharmaceuticals Division quarterly local product sales growth US in 2008 and 2009

|                    | Q3 2008<br>vs. Q3 2007 | Q4 2008<br>vs. Q4 2007 | Q1 2009<br>vs. Q1 2008 | Q2 2009<br>vs. Q2 2008 |
|--------------------|------------------------|------------------------|------------------------|------------------------|
| MabThera/Rituxan   | 14%                    | 15%                    | 6%                     | 6%                     |
| Avastin            | 18%                    | 21%                    | 18%                    | 22%                    |
| Herceptin          | 15%                    | 3%                     | 0%                     | 12%                    |
| Tamiflu            | 6%                     | -83%                   | -94%                   | 710%                   |
| CellCept           | 20%                    | 12%                    | 11%                    | -46%                   |
| Pegasys            | 45%                    | 9%                     | 17%                    | 4%                     |
| NeoRecormon/Epogin | -                      | -                      | -                      | -                      |
| Tarceva            | 9%                     | 5%                     | 0%                     | -5%                    |
| Xeloda             | 9%                     | 8%                     | 11%                    | 12%                    |
| Lucentis           | 15%                    | 19%                    | 21%                    | 21%                    |
| Bonviva/Boniva     | 16%                    | 12%                    | -17%                   | -10%                   |
| Xolair             | 12%                    | 13%                    | 13%                    | 11%                    |
| Valcyte/Cymevene   | 7%                     | 5%                     | 3%                     | 8%                     |
| Pulmozyme          | 13%                    | 24%                    | 14%                    | 4%                     |
| Activase/TNKase    | -2%                    | 13%                    | 49%                    | 20%                    |
| Nutropin           | 1%                     | -1%                    | 1%                     | 2%                     |
| Xenical            | -33%                   | -48%                   | -43%                   | -25%                   |
| Neutrogen          | -                      | -                      | -                      | -                      |
| Rocephin           | -                      | -89%                   | -97%                   | -11%                   |
| Madopar            | -                      | -                      | -                      | -                      |

7. Pharmaceuticals Division quarterly local product sales growth Japan in 2008 and 2009

|                    | Q3 2008<br>vs. Q3 2007 | Q4 2008<br>vs. Q4 2007 | Q1 2009<br>vs. Q1 2008 | Q2 2009<br>vs. Q2 2008 |
|--------------------|------------------------|------------------------|------------------------|------------------------|
| MabThera/Rituxan   | 8%                     | 9%                     | 2%                     | 4%                     |
| Avastin            | 442%                   | 236%                   | 147%                   | 96%                    |
| Herceptin          | 69%                    | 73%                    | 62%                    | 42%                    |
| Tamiflu            | -98%                   | -2%                    | 1207%                  | 30977%                 |
| CellCept           | 15%                    | 10%                    | 15%                    | 8%                     |
| Pegasys            | 49%                    | 39%                    | 36%                    | 30%                    |
| NeoRecormon/Epogin | -9%                    | -16%                   | -8%                    | -1%                    |
| Tarceva            | -                      | 699%                   | 51%                    | 27%                    |
| Xeloda             | 88%                    | 81%                    | 53%                    | 27%                    |
| Lucentis           | -                      | -                      | -                      | -                      |
| Bonviva/Boniva     | -                      | -                      | -                      | -                      |
| Xolair             | -                      | -                      | -                      | -                      |
| Valcyte/Cymevene   | -                      | -                      | -                      | -                      |
| Pulmozyme          | -                      | -                      | -                      | -                      |
| Activase/TNKase    | -                      | -                      | -                      | -                      |
| Nutropin           | -                      | -                      | -                      | -                      |
| Xenical            | -                      | -                      | -                      | -                      |
| Neutrogen          | 0%                     | -13%                   | -22%                   | -13%                   |
| Rocephin           | -1%                    | 5%                     | -3%                    | -2%                    |
| Madopar            | 6%                     | 0%                     | 7%                     | 3%                     |

8. Pharmaceuticals Division quarterly local product sales growth Europe/Rest of World in 2008 and 2009

|                    | Q3 2008<br>vs. Q3 2007 | Q4 2008<br>vs. Q4 2007 | Q1 2009<br>vs. Q1 2008 | Q2 2009<br>vs. Q2 2008 |
|--------------------|------------------------|------------------------|------------------------|------------------------|
| MabThera/Rituxan   | 17%                    | 18%                    | 6%                     | 15%                    |
| Avastin            | 67%                    | 52%                    | 39%                    | 33%                    |
| Herceptin          | 11%                    | 13%                    | 13%                    | 7%                     |
| Tamiflu            | -93%                   | 6%                     | 487%                   | 1423%                  |
| CellCept           | 9%                     | 9%                     | 3%                     | 2%                     |
| Pegasys            | 1%                     | 1%                     | 5%                     | 10%                    |
| NeoRecormon/Epogin | -17%                   | -4%                    | -15%                   | -10%                   |
| Tarceva            | 17%                    | 24%                    | 20%                    | 15%                    |
| Xeloda             | 14%                    | 12%                    | 4%                     | 14%                    |
| Lucentis           | -                      | -                      | -                      | -                      |
| Bonviva/Boniva     | 45%                    | 47%                    | 40%                    | 21%                    |
| Xolair             | -                      | -                      | -                      | -                      |
| Valcyte/Cymevene   | 19%                    | 14%                    | 11%                    | 5%                     |
| Pulmozyme          | -3%                    | 2%                     | -9%                    | 14%                    |
| Activase/TNKase    | 1%                     | 11%                    | 19%                    | 0%                     |
| Nutropin           | -10%                   | -2%                    | -12%                   | 0%                     |
| Xenical            | -6%                    | -7%                    | -11%                   | -8%                    |
| Neutrogen          | -                      | -                      | -                      | -                      |
| Rocephin           | -13%                   | -6%                    | -13%                   | 3%                     |
| Madopar            | 4%                     | 4%                     | 0%                     | -6%                    |

9. Top 20 Pharmaceuticals Division quarterly product sales in 2008 and 2009

| CHF millions       | Q2 2008 | Q3 2008 | Q4 2008 | Q1 2009 | Q2 2009 |
|--------------------|---------|---------|---------|---------|---------|
| MabThera/Rituxan   | 1,460   | 1,472   | 1,584   | 1,481   | 1,617   |
| Avastin            | 1,220   | 1,351   | 1,505   | 1,485   | 1,605   |
| Herceptin          | 1,249   | 1,295   | 1,323   | 1,307   | 1,338   |
| Tamiflu            | 49      | 101     | 181     | 401     | 609     |
| CellCept           | 523     | 513     | 576     | 517     | 410     |
| Pegasys            | 416     | 405     | 445     | 393     | 449     |
| NeoRecormon/Epogin | 450     | 427     | 455     | 378     | 411     |
| Tarceva            | 301     | 298     | 330     | 320     | 323     |
| Xeloda             | 292     | 307     | 331     | 296     | 330     |
| Lucentis           | 225     | 246     | 274     | 279     | 294     |
| Bonviva/Boniva     | 266     | 268     | 333     | 249     | 276     |
| Xolair             | 134     | 145     | 156     | 152     | 161     |
| Valcyte/Cymevene   | 136     | 143     | 149     | 131     | 143     |
| Pulmozyme          | 120     | 120     | 139     | 120     | 128     |
| Activase/TNKase    | 81      | 81      | 97      | 126     | 100     |
| Nutropin           | 98      | 106     | 112     | 104     | 107     |
| Xenical            | 128     | 126     | 112     | 103     | 106     |
| Neutrogen          | 97      | 98      | 114     | 90      | 98      |
| Rocephin           | 85      | 76      | 92      | 77      | 87      |
| Madopar            | 80      | 77      | 80      | 68      | 72      |

10. Pharmaceuticals Division quarterly product sales in US in 2008 and 2009

| CHF millions       | Q2 2008 | Q3 2008 | Q4 2008 | Q1 2009 | Q2 2009 |
|--------------------|---------|---------|---------|---------|---------|
| MabThera/Rituxan   | 706     | 732     | 817     | 769     | 809     |
| Avastin            | 671     | 754     | 841     | 810     | 883     |
| Herceptin          | 349     | 394     | 390     | 390     | 420     |
| Tamiflu            | 30      | 96      | 70      | 15      | 302     |
| CellCept           | 243     | 247     | 321     | 256     | 140     |
| Pegasys            | 95      | 99      | 120     | 101     | 107     |
| NeoRecormon/Epogin | -       | -       | -       | -       | -       |
| Tarceva            | 123     | 117     | 136     | 128     | 125     |
| Xeloda             | 97      | 111     | 131     | 106     | 118     |
| Lucentis           | 225     | 246     | 274     | 279     | 294     |
| Bonviva/Boniva     | 159     | 155     | 208     | 137     | 154     |
| Xolair             | 134     | 145     | 156     | 152     | 161     |
| Valcyte/Cymevene   | 62      | 66      | 76      | 60      | 72      |
| Pulmozyme          | 65      | 69      | 83      | 75      | 73      |
| Activase/TNKase    | 71      | 70      | 86      | 114     | 90      |
| Nutropin           | 94      | 104     | 109     | 101     | 105     |
| Xenical            | 12      | 9       | 8       | 8       | 10      |
| Neutrogen          | -       | -       | -       | -       | -       |
| Rocephin           | 1       | 0       | 1       | 0       | 1       |
| Madopar            | -       | -       | -       | -       | -       |

11. Pharmaceuticals Division quarterly product sales in Japan in 2008 and 2009

| CHF millions       | Q2 2008 | Q3 2008 | Q4 2008 | Q1 2009 | Q2 2009 |
|--------------------|---------|---------|---------|---------|---------|
| MabThera/Rituxan   | 52      | 51      | 68      | 52      | 63      |
| Avastin            | 43      | 57      | 82      | 82      | 100     |
| Herceptin          | 56      | 64      | 87      | 81      | 93      |
| Tamiflu            | 0       | 1       | 71      | 250     | 50      |
| CellCept           | 11      | 9       | 13      | 11      | 13      |
| Pegasys            | 22      | 26      | 35      | 31      | 34      |
| NeoRecormon/Epogin | 114     | 111     | 142     | 115     | 131     |
| Tarceva            | 12      | 11      | 16      | 15      | 17      |
| Xeloda             | 12      | 13      | 17      | 15      | 18      |
| Lucentis           | -       | -       | -       | -       | -       |
| Bonviva/Boniva     | -       | -       | -       | -       | -       |
| Xolair             | -       | -       | -       | -       | -       |
| Valcyte/Cymevene   | -       | -       | -       | -       | -       |
| Pulmozyme          | -       | -       | -       | -       | -       |
| Activase/TNKase    | -       | -       | -       | -       | -       |
| Nutropin           | -       | -       | -       | -       | -       |
| Xenical            | -       | -       | -       | -       | -       |
| Neutrogen          | 97      | 98      | 114     | 90      | 98      |
| Rocephin           | 15      | 14      | 19      | 15      | 17      |
| Madopar            | 5       | 5       | 6       | 5       | 6       |

12. Pharmaceuticals Division quarterly product sales in Europe/Rest of World in 2008 and 2009

| CHF millions       | Q2 2008 | Q3 2008 | Q4 2008 | Q1 2009 | Q2 2009 |
|--------------------|---------|---------|---------|---------|---------|
| MabThera/Rituxan   | 702     | 689     | 699     | 660     | 745     |
| Avastin            | 506     | 540     | 582     | 593     | 622     |
| Herceptin          | 844     | 837     | 846     | 836     | 825     |
| Tamiflu            | 19      | 4       | 40      | 136     | 257     |
| CellCept           | 269     | 257     | 242     | 250     | 257     |
| Pegasys            | 299     | 280     | 290     | 261     | 308     |
| NeoRecormon/Epogin | 336     | 316     | 313     | 263     | 280     |
| Tarceva            | 166     | 170     | 178     | 177     | 181     |
| Xeloda             | 183     | 183     | 183     | 175     | 194     |
| Lucentis           | -       | -       | -       | -       | -       |
| Bonviva/Boniva     | 107     | 113     | 125     | 112     | 122     |
| Xolair             | -       | -       | -       | -       | -       |
| Valcyte/Cymevene   | 74      | 77      | 73      | 71      | 71      |
| Pulmozyme          | 55      | 51      | 56      | 45      | 55      |
| Activase/TNKase    | 10      | 11      | 11      | 12      | 10      |
| Nutropin           | 4       | 2       | 3       | 3       | 2       |
| Xenical            | 116     | 117     | 104     | 95      | 96      |
| Neutrogen          | -       | -       | -       | -       | -       |
| Rocephin           | 69      | 62      | 72      | 62      | 69      |
| Madopar            | 75      | 72      | 74      | 63      | 66      |